Mind Cure makes another key addition to its management team
Mind Cure’s newest Scientific Advisor, Hamilton Morris, is a household name in the world of psychedelics. But don’t take our word for it.
You won’t have to go very far to see for yourself.
“Hamilton’s Pharmacopiea” is an immensely popular series hosted on Vice TV that takes “an incredible journey through the history, chemistry and societal impacts of the world’s most extraordinary drugs.”
Hamilton Morris is more than just a popular media celebrity in the world of psychedelics.
He’s a bona fide expert, a thought leader on the topic. He is frequently featured in psychedelic medicine interviews – on both sides of the microphone.
Now he’s also a Scientific Advisor for Mind Cure Health (CAN:MCUR).
Hamilton Morris joins Mind Cure
On October, 6, 2020; Mind Cure has announced the appointment of Hamilton Morris as a psychedelics expert to the Company’s Advisory Board.
In addition to being a renowned expert and advocate for psychedelic drug medicine, the news release touted Morris’ credentials as “a chemist, filmmaker, and science journalist.”
Philip Tapley, Chairman, President and CEO of Mind Cure, framed the news for shareholders.
“Hamilton is one of the most respected leaders in the industry. His research and journalistic work have helped bring attention to the opportunities available to improve the treatment of mental health through the use of new medicines and treatments. He will be another key piece of our advisory board as we move forward.”
Announcing new additions to a company’s management team doesn’t put any money in the pockets of shareholders – directly. But appointing the right people to achieve operational milestones does make money for investors.
Mind Cure has now made a flurry of additions that also include Canada’s two-time “Top Female Entrepreneur” Kelsey Ramsden, and world-renowned psychedelics researcher Dr. Dan Engle.
The takeaways here for investors?
As noted, it takes the right people in key positions to execute on operational milestones. But these appointments say something more.
Mind Cure is building a strong foundation
To attract such high-caliber personnel requires a strong foundation. Ramsden, Engle and Morris were impressed by what Mind Cure has done to date and they are excited by the direction in which the Company is heading.
Mind Cure is focused on mental health and wellness, the commercial opportunity represented by the Mental Health Crisis.
Morris and Dr. Engle are strong additions to bolster Mind Cure’s psychedelic drug R&D. Expanding Mind Cure’s psychedelics footprint.
Investors like what they see so far.
Since its IPO on September 21st, Mind Cure has moved from CAD$0.20 as high as CAD$0.82. It’s currently sitting at CAD$0.68 – a tidy profit for those who got in early.
Hamilton Morris, Dr. Dan Engle and Kelsey Ramsden like what they see for the future with Mind Cure.
A strong business model to capitalize on the enormous commercial opportunity of bringing new drug therapies to market to address the Mental Health Crisis.
As psychedelic stocks heat up, there is plenty to interest investors with Mind Cure Health.
DISCLOSURE: The writer holds shares in Mind Cure Health. Mind Cure Health is a client of Psychedelic Stock Watch.
